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ABSTRACT 
Discovery and development of a new drug is generally known as a very complex process which takes a lot of time and resources. So 
now a day’s computer aided drug design approaches are used very widely to increase the efficiency of the drug discovery and 
development course. Various approaches of CADD are evaluated as promising techniques according to their need, in between all 
these structure-based drug design and ligand-based drug design approaches are known as very efficient and powerful techniques in 
drug discovery and development. These both methods can be applied with molecular docking to virtual screening for lead 
identification and optimization. In the recent times computational tools are widely used in pharmaceutical industries and research 
areas to improve effectiveness and efficacy of drug discovery and development pipeline. In this article we give an overview of 
computational approaches, which is inventive process of finding novel leads and aid in the process of drug discovery and 
development research. 
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INTRODUCTION 
Computational approaches in drug design, discovery and 
development process gaining very rapid exploration, 
implementation and admiration.Introducing a new drug 
in a market is a very complex, risky and costly process 
in terms of time, money and manpower. Generally it is 
found that drug discovery and development process 
takes around 10-14 years and more than 1 billion dollars 
capital in total 
1
. 
 
 
 
Figure 1: Traditional process of drug discovery and development. 
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So for reducing time, cost and risk borne factors 
computer aided drug design (CADD) method is widely 
used as a new drug design approach. It has been seen 
that by the use of CADD approaches we can reduced the 
cost of drug discovery and development up to 50% 
2
. 
CADD consist use of any software program based 
process for establishing a standard to relate activity to 
structure 
3
. 
  
 
Figure 2: General Principle for Drug design through CADD. 
Major types of approaches in CADD 
There are mainly two types of approaches for drug design through CADD is the following: 
1. Structure based drug design / direct approach 
2. Ligand based drug design / indirect approach 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: General Representation of workflow for CADD. 
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1. Structure-based drug design 
In SBDD, structure of the target protein is known and 
interaction or bio-affinity for all tested compounds 
calculate after the process of docking; to design a new 
drug molecule, which shows better interaction with 
target protein 
4
. 
 
 
Figure 4: Layout of SBDD 
5
. 
 
Overview of the process involved in SBDD 
SBDD runs through multiple cycles before the 
optimized lead reached into clinical trials. The first 
cycle comprises isolation, purification and structure 
determination of the target protein by one of three key 
methods: like X-ray crystallography, homology 
modeling or NMR. Using compounds comes through 
virtual screening of different databases are placed into a 
selected region (active site) of the protein. These 
compounds are scored and ranked on the bases of steric, 
hydrophobic, electrostatic interaction of these molecules 
with the active site of target protein. Top ranked 
compounds are tested with biochemical assays. 
Second cycle comprises structure determination of the 
protein in complex with the most optimistic lead of the 
first cycle, the one with minimum micro-molar 
inhibition in-vitro, and shows sites of the compound 
which can be optimized for further increment in the 
potency. After several additional cycles like synthesis of 
lead, further optimization of lead through complex 
structure of protein with lead compound, the optimized 
compounds generally show marked increment in the 
target specificity and binding affinity 
6
. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Steps involved in SBDD. 
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2. Ligand-Based drug design 
In LBDD, 3D structure of the target protein is not known 
but the knowledge of ligands which binds to the desired 
target site is known. These ligands can be used to 
develop a pharmacophore model or molecule which 
possesses all necessary structural features for bind to a 
target active site. 
 
  
Figure 6: Outline of process involved in LBDD 
7
. 
Generally ligand-based techniques are pharmacophore based approach and quantitative-structure activity relationships 
(QSARs). In LBDD it is assumed that compounds which having similarity in their structure also having the same 
biological action and interaction with the target protein 
8
. 
Virtual screening  
Virtual screening has been worked as a most convenient tool now a day to find out the most favorable bioactive 
compounds with the help of information about the protein target or known active ligands. In the recent time virtual 
screening is known as a mind blowing alternative of high-throughput screening mainly in terms of cost effectiveness 
and probability of finding most appropriate novel hit through filter the large of libraries of compounds 
9
. 
 
Figure 7: Overview of Virtual screening process 
10
. 
There are generally two types of virtual screening 
approaches like structure-based virtual screening 
(SBVS) and ligand-based virtual screening (LBVS), 
SBVS method rely on the structure of target protein 
active site and LBVS method is based on estimation of 
calculated similarity between the known active and 
compound come from databases. 
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Figure 8: Schematic diagram of VS process for SBDD & LBDD 
11
 
Molecular docking 
Molecular docking is in-silico method which predicts 
the placement of small molecules or ligands within the 
active site of their target protein (receptor). It is mainly 
used to accurate estimation of most favorable binding 
modes and bio-affinities of ligands with their receptor, 
presently it has been broadly applied to virtual screening 
for the optimization of the lead compounds. 
  
 
Figure 9: Process of Docking 
12
 
Molecular docking methodology comprises mainly three 
goals which are interconnected to each other like: 
prediction of binding pose, bio affinity and virtual 
screening. In the molecular docking method the basis 
tools are search algorithm and scoring functions for 
creating and analyzing conformations of the ligand 
13
. 
ADVANTAGES OF CADD 
 Through it we can reduce the synthetic and 
biological testing efforts 
14
. 
 It gives the most promising drug candidate by 
eliminate the compounds with undesirable 
properties (poor efficacy, poor ADMET etc.) 
through in silico filters 
15
. 
 It is a Cost-effective, time saving, Rapid and 
automatic process. 
 Through it we can know about the drug-receptor 
interaction pattern. 
 It gives compounds with high hit rates through 
searching huge libraries of compounds in silico in 
comparison to traditional high throughput screening 
16
. 
 These approaches minimize chances of failures in 
the final phase. 
CONCLUSION AND FUTURE ASPECTS  
Computer aided drug design is an efficient tool in the 
area of drug discovery and development, through it we 
can find the most promising drug candidate in a very 
cost-effective way. It always provides a hope for 
betterment in drug discovery area. In the past years 
through Computer aided drug design many impressive 
researches are achieved so it will play a very much 
important role in the near future. With the current 
achievement’s, there is a promising future of computer 
aided drug design to aid drug discovery of many more 
curatives in future. 
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